Study #2024-1423
A phase 1/2 safety, dose-finding, and pharmacokinetics study of VNX-101 gene therapy in patients with relapsed or refractory CD19+ B cell acute Lymphoblastic Leukemia
MD Anderson Study Status
Enrolling
Treatment Agent
Description
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia (ALL).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
B-cell Acute Lymphoblastic Leukemia
Study phase:
Physician name:
Nicholas Short
Department:
Leukemia
For general questions about clinical trials:
1-833-802-0471
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.